TVTX — Expected Completion of Clinical Trial for Sparsentan in IgA Nephropathy
Jul 1, 2026, 4:00:00 AM UTC
Summary
Travere Therapeutics, Inc. is expected to complete its clinical trial for Sparsentan, a dual-acting angiotensin receptor blocker and endothelin receptor antagonist, in treating patients with IgA Nephropathy on July 1, 2026. The study, which began on December 11, 2018, focuses on patients at high risk of renal failure and evaluates the safety and effectiveness of Sparsentan compared to the current standard treatment, irbesartan. Approximately 380 patients are enrolled in this Phase 3 trial, assessing changes in proteinuria and estimated glomerular filtration rate (eGFR) over the course of 114 weeks, followed by an optional open-label extension period. The anticipated completion of the trial could provide insights into the potential benefits of Sparsentan as an alternative treatment for this condition.
Company
TRAVERE THERAPEUTICS INC (TVTX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.retrophin.comSimilar Events
Expected Completion of Clinical Trial for Sparsentan Treatment in Pediatrics
Travere Therapeutics, Inc. anticipates the completion of its Phase 2 clinical trial studying Sparsentan treatment in pediatric patients with proteinuric glomerular diseases by April 12, 2027. This multicenter, open-label study targets approximately 67 subjects aged 1 to 18 years, focusing on multiple conditions including Focal Segmental Glomerulosclerosis and immunoglobulin A nephropathy. The trial will evaluate the long-term safety, tolerability, and efficacy of Sparsentan, which may significantly impact treatment options for these patients who currently face limited alternatives.
Clinical Trial CompletionExpected Completion Date of Clinical Trial Study of Sparsentan in FSGS
Travere Therapeutics, Inc. anticipates the completion of its clinical trial for Sparsentan, a novel dual-action angiotensin receptor blocker and endothelin receptor antagonist, in treating patients with focal segmental glomerulosclerosis (FSGS) by February 1, 2026. The trial assesses Sparsentan's efficacy in improving kidney function against the standard treatment, irbesartan, primarily through changes in proteinuria and estimated glomerular filtration rate. Approximately 380 participants are enrolled in this study, aimed at high-risk patients with persistent proteinuria despite current therapies. The trial is currently active but not recruiting additional participants, as it approaches its primary completion date for the double-blind phase of the study.
Clinical Trial CompletionExpected Clinical Trial Completion for SPN-812 Study
Supernus Pharmaceuticals, Inc. is expected to complete the open-label study evaluating the long-term safety and efficacy of SPN-812 (Viloxazine Extended-release Capsule) by September 1, 2026. This multicenter study focuses on pediatric subjects with ADHD who have previously participated in earlier trials. It assesses the drug's safety and efficacy through both Optimization and Maintenance phases, with an enrollment of approximately 1,400 participants. The study is currently active but not recruiting new subjects, following earlier Phase 2 and Phase 3 trials. Completion of this study may provide critical data that could influence future market acceptance of SPN-812 in treating ADHD.
Clinical Trial CompletionExpected Completion of Clinical Trial for Felzartamab in IgAN
Biogen is set to complete a clinical trial evaluating felzartamab's effects on adults with Immunoglobulin A Nephropathy (IgAN) on June 5, 2029. The trial aims to assess the efficacy of felzartamab relative to a placebo on proteinuria and kidney functions, involving an enrollment of 454 participants. This Phase 3 trial is crucial as it could provide insights into the drug's potential as a treatment option for IgAN, a serious kidney condition characterized by high levels of immunoglobulin A in the kidneys and associated with significant health risks.
Clinical Trial Completion